Oral drug cuts heart disease-related lipoprotein(a) levels by up to 65% in early trial

Embargoed until: Publicly released: 2023-08-28 22:00

Australia; VIC

CC-0

Australian and US scientists say an orally-administered drug called muvalaplin, which is a small molecule, cut levels of lipoprotein(a) by up to 65% in 93% of healthy patients who took it for 14 days, based on a trial in 114 people funded by the drug's manufacturer, Eli Lilly. Lipoprotein(a) is linked to clogged arteries and narrowing of the heart valves. The trial also showed the drug was safe and well tolerated by patients. This is an initial study designed to assess safety, so longer and larger trials will be required to confirm the drug's effectiveness, the experts say.

Media release

From: JAMA

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation

About The Study: Muvalaplin was not associated with tolerability concerns and lowered lipoprotein(a) (Lp[a]) levels up to 65% following daily administration for 14 days in this first-in-human phase 1 study involving healthy participants. Lipoprotein(a) is associated with atherosclerotic disease and aortic stenosis. Longer and larger trials will be required to further evaluate safety, tolerability, and effect of muvalaplin on Lp(a) levels and cardiovascular outcomes.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA

Research:Paper

Organisation/s: Monash University

Funder: This study was sponsored and funded by Eli Lilly and Company, manufacturer of muvalaplin. ProScribe–Envision Pharma Group provided administrative support to the authors.

Media Contact/s

Contact details are only visible to registered journalists.